Senior Immunology Specialist ProImmune, Inc. Sarasota, Florida
Description: Part 1: Immunogenicity risk assessment is critical to winning in today’s drug market. Learn from real-world case studies applying MAPPS, T cell proliferation, MHC-peptide binding and cytokine release assays. Part 2: Understand the current options and context to next-generation target binding reagents that overcome many of the current constraints of research antibodies. This portion of the presentation will focus on animal-free monoclonal binding reagents 10x smaller than antibodies based on ankyrin-repeat proteins with demonstrated success in a wide range of applications. Learn how these high affinity tools can be used to interrogate target proteins providing solutions to problems that were previously not addressable.
Learning Objectives:
Provide a summary of best-in-class Immunogenicity assessment tools with case studies to demonstrate how and when the assays can be incorporated into various therapeutic programs.
Describe a novel animal-free ankyrin-repeat technology and demonstrate how available these tools will address the challenges associated with antibody generation, including customization, cost, timing and requirements of species-specific and isotype controls.
Detail in-house and collaborative data to highlight the use in diverse applications, improvements in protocol, advantages in size and achievements in areas that were previously unsuccessful.
